Intra-Cellular Therapies, Inc. (ITCI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Intra-Cellular Therapies, Inc. (ITCI)
Company Performance

Current Price

as of Dec 06, 2024

$84.55

P/E Ratio

N/A

Market Cap

$8.96B

Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Metrics

Overview

  • HQBedminster, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerITCI
  • Price$84.55+0.55%

Trading Information

  • Market cap$8.96B
  • Float93.46%
  • Average Daily Volume (1m)515,383
  • Average Daily Volume (3m)546,303
  • EPS-$0.86

Company

  • Revenue$613.73M
  • Rev growth (1yr)39.00%
  • Net income-$26.32M
  • Gross margin91.27%
  • EBITDA margin-22.07%
  • EBITDA-$38.71M
  • EV$6.75B
  • EV/Revenue11.00
  • P/EN/A
  • P/S14.57
  • P/B7.83